Making a case for long-term, low-intensity warfarin therapy


Investigators for the Prevention of Recurrent Venous Thromboembolism (PREVENT) study noted a significant reduction in the risk of recurrent deep-vein thromboembolism (DVT) and pulmonary embolism (PE) in study participants treated with low-intensity warfarin therapy (target International Normalized Ratio [INR], 1.5-2) compared to those taking placebo. The low-intensity warfarin regimen was so beneficial to patients that the National Heart, Lung, and Blood Institute terminated the study early.

Related Content
© 2024 MJH Life Sciences

All rights reserved.